Total neoadjuvant therapy is associated with improved overall survival and pathologic response in pancreatic adenocarcinoma.

ABSTRACT:

Background

Few studies have evaluated outcomes of total neoadjuvant therapy (TNT) compared with single modality neoadjuvant therapy (SMNT) or surgery first (SF) for pancreatic ductal adenocarcinoma (PDAC).

Methods

A single-institution retrospective review of PDAC patients who underwent pancreatectomy was conducted (1993-2019). Overall survival (OS) estimates from diagnosis and from surgery were determined using Kaplan-Meier methods; Cox proportional hazards models adjusted for covariates.

Results

Surgery was performed upfront (SF) in 168 (46.9%), while 111 (31.0%) had chemotherapy or chemoradiation before resection (SMNT), and 79 (22.1%) underwent TNT (chemotherapy and chemoradiation). Resection margins were more frequently R0 in the TNT group (86.1%) compared with SM

SUBMITTER: Villano AM 

PROVIDER: S-EPMC9340441 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature